EUDA Health Holdings Limited announced on September 10, 2025, that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has signed a Letter of Intent (LOI) to potentially acquire GO POSB Organoids Pte Ltd. GO POSB is a Singapore-based biotechnology company known for its proprietary induced pluripotent stem cell (iPSC) platform.
The iPSC platform can reprogram human blood cells into clinical-grade, therapeutics-ready stem cells, offering pluripotency without the ethical concerns associated with embryonic stem cells. These iPSCs have vast applications in drug discovery, disease modeling, regenerative medicine, and future cell-based therapies.
Under the LOI, EUDA and GO POSB are exploring the establishment of an iPSC laboratory and cultivation facility in Shenzhen, China, to store, expand, and distribute iPSC solutions across China. EUDA will provide funding for this build-out and collaborate with Singapore’s Agency for Science, Technology and Research (A*STAR) to advance iPSC research and clinical trials.
This initiative aims to position EUDA as a B2B supplier of iPSC solutions to the downstream healthcare ecosystem, including hospitals and biotech developers. It also opens opportunities for off-the-shelf iPSC-derived products for Asia’s wellness and aesthetics markets, directly complementing EUDA’s growing portfolio of stem cell treatments and supplements.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.